Yu T, Jiao J, Wu M
Front Immunol. 2025; 16:1499590.
PMID: 40078993
PMC: 11897482.
DOI: 10.3389/fimmu.2025.1499590.
Bruins W, Rentenaar R, Newcomb J, Zheng W, Ruiter R, Baardemans T
Hemasphere. 2024; 8(11):e70039.
PMID: 39544624
PMC: 11561653.
DOI: 10.1002/hem3.70039.
De Novellis D, Derudas D, Vincelli D, Fontana R, Pepa R, Palmieri S
Eur J Haematol. 2024; 114(1):105-114.
PMID: 39370303
PMC: 11613624.
DOI: 10.1111/ejh.14314.
Dai Y, Luo L, Wei Z, Cheng P, Luo J, Li J
Ann Hematol. 2024; 103(10):4057-4063.
PMID: 39046511
PMC: 11512853.
DOI: 10.1007/s00277-024-05892-9.
Bhowmick K, von Suskil M, Al-Odat O, Elbezanti W, Jonnalagadda S, Budak-Alpdogan T
Heliyon. 2024; 10(12):e33091.
PMID: 39021902
PMC: 11252793.
DOI: 10.1016/j.heliyon.2024.e33091.
Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38.
Li S, Chen D, Yang Y, Guo H, Liu D, Sun N
Front Immunol. 2024; 15:1398508.
PMID: 38983860
PMC: 11231100.
DOI: 10.3389/fimmu.2024.1398508.
Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity.
Liu W, Yu J, Sun K, Song Q, Li Y, He Y
Front Immunol. 2024; 15:1410457.
PMID: 38765013
PMC: 11099226.
DOI: 10.3389/fimmu.2024.1410457.
What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study.
DArena G, Vitale C, Pietrantuono G, Villani O, Mansueto G, DAuria F
Cancers (Basel). 2024; 16(2).
PMID: 38275909
PMC: 10814247.
DOI: 10.3390/cancers16020469.
Translating B cell immunology to the treatment of antibody-mediated allograft rejection.
Heeger P, Haro M, Jordan S
Nat Rev Nephrol. 2024; 20(4):218-232.
PMID: 38168662
DOI: 10.1038/s41581-023-00791-0.
Cancer drugs with high repositioning potential for Alzheimer's disease.
Majeed J, Sabbagh M, Kang M, Lawrence J, Pruitt K, Bacus S
Expert Opin Emerg Drugs. 2023; 28(4):311-332.
PMID: 38100555
PMC: 10877737.
DOI: 10.1080/14728214.2023.2296079.
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience.
De Novellis D, Fontana R, Palmieri S, Pepa R, Di Perna M, Cetani G
Target Oncol. 2023; 18(6):885-892.
PMID: 37747623
PMC: 10663178.
DOI: 10.1007/s11523-023-01001-4.
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment.
Elbezanti W, Challagundla K, Jonnalagadda S, Budak-Alpdogan T, Pandey M
Pharmaceuticals (Basel). 2023; 16(3).
PMID: 36986514
PMC: 10056051.
DOI: 10.3390/ph16030415.
Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance.
De Novellis D, Fontana R, Giudice V, Serio B, Selleri C
Int J Mol Sci. 2023; 24(1).
PMID: 36614086
PMC: 9820921.
DOI: 10.3390/ijms24010645.
Targeting CD38 for acute leukemia.
Zhong X, Ma H
Front Oncol. 2022; 12:1007783.
PMID: 36313735
PMC: 9597453.
DOI: 10.3389/fonc.2022.1007783.
Daratumumab Interferes with Allogeneic Crossmatch Impacting Immunological Assessment in Solid Organ Transplantation.
Ho C, Putnam K, Peiter C, Herczyk W, Gerlach J, Lu Y
J Clin Med. 2022; 11(20).
PMID: 36294380
PMC: 9605360.
DOI: 10.3390/jcm11206059.
Research progress in the role of CD38 in clinical tumor treatment.
He Z, Liu X, Zhou Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022; 47(7):952-959.
PMID: 36039593
PMC: 10930288.
DOI: 10.11817/j.issn.1672-7347.2022.210351.
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.
Leleu X, Martin T, Weisel K, Schjesvold F, Iida S, Malavasi F
Ann Hematol. 2022; 101(10):2123-2137.
PMID: 35943588
PMC: 9463192.
DOI: 10.1007/s00277-022-04917-5.
Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment.
Xu Q, Liu X, Mohseni G, Hao X, Ren Y, Xu Y
Cancer Cell Int. 2022; 22(1):242.
PMID: 35906622
PMC: 9338646.
DOI: 10.1186/s12935-022-02664-1.
Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma.
Lebel E, Nachmias B, Pick M, Even-Zohar N, Gatt M
J Clin Med. 2022; 11(7).
PMID: 35407416
PMC: 9000075.
DOI: 10.3390/jcm11071809.
Isolation, Maintenance and Expansion of Adult Hematopoietic Stem/Progenitor Cells and Leukemic Stem Cells.
Mayer I, Hoelbl-Kovacic A, Sexl V, Doma E
Cancers (Basel). 2022; 14(7).
PMID: 35406494
PMC: 8996967.
DOI: 10.3390/cancers14071723.